Abstract B57: RNAi Nanotechnology for Cancer Target Validation and Therapy

RNA interference (RNAi) represents a promising strategy for identification and validation of putative therapeutic targets, and for treatment of a myriad of important human diseases including cancer. The ubiquitous application of RNAi in cancer research and therapy is nevertheless hindered by the challenge of effective systemic in vivo delivery of RNAi agents (e.g., siRNA) to solid tumors, which requires overcoming of multiple physiological barriers, such as enzymatic degradation, rapid elimination by renal excretion or by the mononuclear phagocyte system (MPS), poor tumor penetration, and insufficient cellular uptake and endosomal escape. Here we will describe the rational design and development of unique nanoparticle platforms to address these obstacles. These siRNA nanoparticles have been successfully applied to evaluate the therapeutic role of different targets (e.g., prohibitin1) in treating solid tumors, and have demonstrated significant potential for the clinical development of novel cancer therapies.Note: This abstract was not presented at the conference.Citation Format: Jinjun Shi. RNAi Nanotechnology for Cancer Target Validation and Therapy. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr B57.

Source: Cancer Research - January 15, 2017 Category: Cancer & Oncology Authors: Jinjun Shi Tags: Tumor Immunology/Immunotherapy Source Type: research